MAIN PROGRAM
65th Annual MeetingSociety of Thrombosis and
Hemostasis Research
Across Borders
22 – 26 February 2021simply online
Interdisciplinarity in Thrombosis and HemostasisAnesthesiology l Angiology l Cardiology l Gynecology/Obstetrics l
Hemato-oncology l Hepatology/Gastroenterology l Laboratory medicine lNeurology l Pediatrics l Transfusion medicine
www.gth2021.org
3
Platzhalter Inserat
TABLE OF CONTENTS
Welcome Address 4
Acknowledgments 5
Organizing Committees 7
GTH 2021 Abstract Reviewers 8
General Information 9
Information about the virtual congress platform 10
Program overview 12 – 21
Scientific Program 22 – 52
Poster List 54 – 57
List of Chairs, Speakers and Authors 58 – 59
Industrial Exhibition 60 – 61
List of Sponsors 62
54
WELCOME ADDRESS ACKNOWLEDGMENTS
BIENVENUE…...to the 65th Annual Meeting of the Society of Thrombosis and Hemostasis Research. First online!
ACROSS (NEW) BORDERSFor the fi rst time in its history, the GTH congress was scheduled to be held in the French-speaking part of Switzerland: “La Romandie”.
I really hoped that this attractive location would have enabled participants from all Switzerland, Germany and Austria, France and Italy, and possibly from other European countries to gather in Lausanne for four days of science and clinical practice in hemostasis.
The tiny SARS-CoV-2 changed our big plans. Because of the ongoing COVID-19 pandemic, we were conside-ring a hybrid meeting, but we had eventually to opt for an exclusively online congress. Although this choice will cause some burning loss, it will open new opportunities as well.
We will miss the wonderful surroundings of Lausanne with its vineyards, the mountains, and the lake. We will miss the encounters and lively discussions. We will miss friends and colleagues.
However, we will profi t from the digital network. Possibly, the online congress will attract curious minds who would not have attended a face-to-face GTH meeting, thus widening our audience. For Abstracts and Oral Communications, online discussion forums will allow interacting with the authors during the whole congress. The lively 3D industrial exhibition will be accessible for a whole month. The online congress format will solve the problem of choosing between parallel sessions: all presentations will be available online so that you will be able to listen to them at your best convenience. You could even organize a “beer & pizza workshop”, enjoying your preferred talks with your team ... Just think ACROSS BORDERS and let us make the best out of the situation!
ACROSS (OLD) BORDERSHemostasis is just fascinating! In my experience, one of the several reasons is its interdisciplinary character, which we realize daily discussing clinical cases with colleagues from other medical specialties: in emergency rooms and operating theatres, on pediatric wards, in the lab and in clinics as diverse as hepatology, obstetrics, or hematology.
The 2021 GTH congress will focus on interdisciplinary aspects of hemostasis, opening the doors to colleagues from other medical fi elds, and opening the minds towards different points of view and ways of thinking hemostasis.
ACROSS BORDERSWe have a privileged profession! Daily, we meet human beings in quite vulnerable phases of their lives – this is our greatest responsibility. Doing research, we can create knowledge – this is our greatest challenge.
Clinical passion and research! My fi rst medical teacher, Carlofelice Beretta-Piccoli (1946-1994) used to say to us young residents and exemplifi ed through his own professional life that an accomplished physician is intel-lectually curious, scientifi cally accurate and able to “appassionarsi al destino del paziente”.
The motto of the 65th Annual Meeting of the Society of Thrombosis and Hemostasis Research – ACROSS BORDERS – stands for all of this: Internationality, Interdisciplinary Hemostasis, Science and Humanity... and the digital barrier.
We – the local, Swiss and international organizing committees – have been working for setting up the frame conditions for a successful scientifi c congress. However, only if you will submit your best research abstracts and actively participate, the congress will become “enriching and memorable”... even if simply online!
Bienvenue...
Lorenzo Alberio Congress president
The Organizers of GTH 2021 gratefully acknowledge the support of the following companies:
GOLD SPONSORS
PLATINUM SPONSORS
SILVER SPONSORS
7
Platzhalter Inserat "Save the Date 2022"
ORGANIZING COMMITTEES
Congress President
Lorenzo Alberio, Lausanne (CH)
Local Organizing Committee
Alessandro Aliotta, Lausanne (CH)
Debora Bertaggia Calderara, Lausanne (CH)
Maxime Zermatten, Lausanne (CH)
National Organizing Committee
Alessandro Casini, Geneva (CH)
Giuseppe Colucci, Lugano (CH)
Pierre Fontana, Geneva (CH)
Lukas Graf, St. Gallen (CH)
Inga Hegemann, Zurich (CH)
Christian Heinis, Lausanne (CH)
Johanna Kremer, Bern (CH)
Thomas Lecompte, Geneva (CH)
Maria Martinez, Basel (CH)
Michael Nagler, Bern (CH)
Emanuelle Scala, Lausanne (CH)
Verena Schröder, Bern (CH)
Jan-Dirk Studt, Zurich (CH)
International Organizing Committee
Marie-Christine Alessi, Marseille (FR)
Cihan Ay, Wien (AT)
Marco Cattaneo, Milano (IT)
Yves Gruel, Tours (FR)
Bettina Kemkes-Matthes, Giessen (DE)
Christoph Male, Wien (AT)
Pierre Mangin, Strasbourg (FR)
Christine Mannhalter, Wien (AT)
Patrizia Noris, Pavia (IT)
Alessandro Pecci, Pavia (IT)
Ulrich Sachs, Giessen (DE)
Barbara Zieger, Freiburg (DE)
Theme Leaders
AnesthesiologyGabriele Casso, Lugano (CH)Carlos Marcucci, Lausanne (CH)
AngiologyLucia Mazzolai, Lausanne (CH)Marc Righini, Geneva (CH)
CardiologyTobias Rutz, Lausanne (CH)Marco Valgimigli, Bern (CH)
Gynecology/ObstetricsDavid Baud, Lausanne (CH)Daniel Surbek, Bern (CH)
Hemato-oncologyBernhard Gerber, Bellinzona (CH)Walter Wuillemin, Luzern (CH)
HepatologyAndrea De Gottardi, Lugano (CH)Guido Stirnimann, Bern (CH)
Laboratory medicineWolfgang Korte, St. Gallen (CH)Dimitrios Tsakiris, Basel (CH)
Lab techniciansEvelyne Giabbani, Zurich (CH)Anita Gähler, Luzern (CH)Silvio Kathriner, Luzern (CH)
NeurologyUrs Fischer, Bern (CH)Patrik Michel, Lausanne (CH)
PediatricsManuela Albisetti, Zurich (CH)Mattia Rizzi, Lausanne (CH)
Transfusion medicineMichel Prudent, Lausanne (CH)Sacha Zeerleder, Bern (CH)
98
GTH 2021 ABSTRACT REVIEWERS GENERAL INFORMATION
Walter Ageno
Lorenzo Alberio
Manuela Albisetti
Marie-Christine Alessi
Günter Auerswald
Cihan Ay
Jürg Hans Beer
Gregor Bein
Ho-Tin-Noé Benoit
Christoph Bidlingmaier
Christoph Binder
Ingvild Birschmann
Arijit Biswas
Christoph Bode
Judith Bouchardy
Hans-Hermann Brackmann
Maria Alexandra Brehm
Marianne Brodmann
Ulrich Budde
Heiko Matthias Bugger
Ilaria Canobbio
Alessandro Casini
Gabriele Casso
Giancarlo Castaman
Marco Cattaneo
Kenneth Clemetson
Giuseppe Colucci
Judith Cosemans
Daniel Duerschmied
Wolfgang Eberl
Sabine Eichinger-Hasenauer
H. C. J. Eikenboom
Anita Gähler
Johanna Gebhart
Christof Geisen
Andreas Greinacher
Yves Gruel
Sylvia Haas
Viola Hach-Wunderle
Sebastian Harder
Job Harenberg
Alexander Haushofer
Christian Heinis
Marc Heizmann
Sabine Herterich
Katharina Holstein
Ingrid Hrachovinova
Kurt Huber
Bernd Jilma
Kerstin Jurk
Beate Kehrel
Bettina Kemkes-Matthes
Karim Kentouche
Robert Klamroth
Paul Knöbl
Ralf Knöfler
Oliver Königsbrügge
Jürgen Koscielny
Thomas Kühne
Karin Kurnik
Paul Alexander Kyrle
Bernhard Lämmle
Florian Langer
Riitta Lassila
Hans-Jürgen Laws
Thomas Lecompte
Marcel Levi
Edelgard Lindhoff-Last
Birgit Linnemann
Michael Makris
Christoph Male
Pierre Mangin
Christine Mannhalter
Carlo Marcucci
Steffen Massberg
Sara Meyer
Wolfgang Miesbach
Ulrike Nowak-Göttl
Thomas Nührenberg
Martin Olivieri
Ingrid Pabinger-Fasching
Anna Pavlova
Alessandro Pecci
Dirk Peetz
Sirak Petros
Flora Peyvandi
Klaus T. Preissner
Zoltán Prohászka
Peter Quehenberger
Hanno Riess
Marc Righini
Jürgen Ringwald
Mattia Rizzi
Hannelore Rott
Tobias Rutz
Sentot Santoso
Emmanuelle Scala
Rüdiger E. Scharf, FAHA
Reinhard Schneppenheim
Ute Scholz
Verena Schroeder
Roger Schutgens
Michael Spannagl
Henri Spronk
Werner Streif
Jan-Dirk Studt
Christoph Sucker
Hugo ten Cate
Thomas Thiele
Mauro Torti
Minna Voigtländer
Nicolas von der Weid
Anne Sophie von Krogh
Ulrich Walter
Johann Wojta
Alisa S. Wolberg
Walter Alfred Wuillemin
Rainer B. Zotz
Organizer
Society of Thrombosis and Hemostasis ResearchGertrudenstrasse 9DE-50667 KölnP +49 221 423 346 26F +49 221 423 346 [email protected]
Congress president
Lorenzo AlberioMédecin chefCentre Hospitalier Universitaire VaudoisService et Laboratoire central d‘hématologieRue du Bugnon 46CH-1011 [email protected]
Professional congress organizer
Meister ConCept GmbHBahnhofstrasse 55CH-5001 AarauP +41 62 836 20 [email protected]
The organizer of the industrial exhibition and the satellite symposia is Meister ConCept GmbH, Aarau / Switzerland.
Congress language
The official congress language is English. The educational and scientific lectures will be held in English (no simultaneous translations).
Satellite symposia and workshops will be held in German or English.
Registration fee incl. Payment & Account information
Registration fee
GTH Member CHF 200.00
GTH Non-Member CHF 245.00
PhD student*, MTA, nursing staff, physician in training*, retired member
CHF 100.00
Student* CHF 40.00
*Proof of current status needs to be sent to the Congress organizer by mail. Only then a deduction can be granted.
Cancellation policy
All cancellations must be electronically mailed. Refund of registration fee will be as follows:
• Cancellations received up and including October 31th 2020: Full refund
• Cancellations received up and including December 31th 2020: 50%
• Cancellations received after December 31th 2020: no refund will be made
• Registration with no-show will be invoiced.
Credit Allowance
Certificate of Attendance with EFN codesPlatzhaltertext: Nequi in pa si occus. Ga. Ut odi-ciate ex eos ut et iundipsam eum, as debitibus essi ut fuga. Nemost, quodici umquodit, conem intus alita pratemp orepuda consecatio dit odias molorrum eum quamus esectate ex enestrum etur am nusam cuptatur?
Certificate of Attendance without EFN codesPlatzhaltertext: Nequi in pa si occus. Ga. Ut odi-ciate ex eos ut et iundipsam eum, as debitibus essi ut fuga. Nemost, quodici umquodit, conem intus alita pratemp orepuda consecatio dit odias molorrum eum quamus esectate ex enestrum etur am nusam cuptatur?
Digital poster exhibition
Platzhaltertext: Nequi in pa si occus. Ga. Ut odi-ciate ex eos ut et iundipsam eum, as debitibus essi ut fuga. Nemost, quodici umquodit, conem intus alita pratemp orepuda consecatio dit odias molorrum eum quamus.
Grants and awards of the GTH
Platzhaltertext: Nequi in pa si occus. Ga. Ut odi-ciate ex eos ut et iundipsam eum, as debitibus essi ut fuga. Nemost, quodici umquodit, conem intus alita pratemp orepuda consecatio dit odias molorrum eum quamus
10
INFORMATION ABOUT THE VIRTUAL CONGRESS PLATFORM
Platzhalter Inserat "SOBI"
Platzhalter Titel
Platzhaltertext: Bus apid evenestia pedi nes aut as ipsa isque pliquate porestias mint rest, quae re si oditam rest omnitium fugiati orporrovid utaecta quaeperia aped eosandam, te non expliquam, nitempe rsperovit quo blabor audaesciur? Aquo toremporrum deseque maion ra ipici verorro que ea ium volorun tiberia tusapitat velessedi con pelitatur? Em ea ne sandestia quam quasinust endam siminctios amus excernam, aut ent quibus natasperunto volupti aectio odi tem quo enimusam que volore, cus et as rae-stecerior alit esequae pe non nis ipiciatat.
Ore cones conescit estisquo il ipsunt miliqui ipsa volores verspel lestorporese suntiis comnihillaut enit, qui conet laborum dolori omnistrum vident essin cuptat.Em lam labo. Nam, ut denet este quiatus quisti con pra cum re consequ untium reperch illiquis nullam repedit lab is ea solore volorrum fuga. Rum doluptiur, am hillut fuga. Olor sequasp errorupta di iur secesto blam harchil in res sin porem aut asperumquam, quis corrorunt et ut aut eum qui consequid ea sequasi-minte vellaboria venihitaquae pedia dit opta debis di verum sequis es invendit, nosserit fugiti voluptusa-ped magnima gnitas doloremos illa vollacium adit liquatintio berum vit ea dolluptis doluptas cusapicilles sa dempost, sant unt hit il eiunt.
Platzhalter Titel
Platzhaltertext: Bus apid evenestia pedi nes aut as ipsa isque pliquate porestias mint rest, quae re si oditam rest omnitium fugiati orporrovid utaecta quaeperia aped eosandam, te non expliquam, nitempe rsperovit quo blabor audaesciur? Aquo toremporrum deseque maion ra ipici verorro que ea ium volorun tiberia tusapitat velessedi con pelitatur? Em ea ne sandestia quam quasinust endam siminctios amus excernam, aut ent quibus natasperunto volupti aectio odi tem quo enimusam que volore, cus et as rae-stecerior alit esequae pe non nis ipiciatat.
Platzhalter Titel
Platzhaltertext: Bus apid evenestia pedi nes aut as ipsa isque pliquate porestias mint rest, quae re si oditam rest omnitium fugiati orporrovid utaecta quaeperia aped eosandam, te non expliquam, nitempe rsperovit quo blabor audaesciur? Aquo toremporrum deseque maion ra ipici verorro que ea ium volorun tiberia tusapitat velessedi con pelitatur? Em ea ne sandestia quam quasinust endam siminctios amus excernam, aut ent quibus natasperunto volupti aectio odi tem quo enimusam que volore, cus et as rae-stecerior alit esequae pe non nis ipiciatat.
1312
Rome Barcelona Sydney Lausanne Outside the congress platform(by pre-registration)
MTA-Workshop Teil 1
Pause
MTA-Workshop Teil 2
Master Class
Pause
Master Class
WET-Workshop
TreffenHämostaseologie-AssistentInnen
Ständige Kommission PädiatriePause Ständige Kommission
Nachwuchs / Junge Hämostaseologie
BMA-Workshop Ständige Kommission Hämophilie
Ständige Kommission Labor
Opening Ceremony
08:00
08:30
09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
17:30
18:00
18:30
19:00
19:30
20:00
20:30
08:00
08:30
09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
17:30
18:00
18:30
19:00
19:30
20:00
20:30
PROGRAM OVERVIEW | MONDAY, 22.02.2021
Plenary State of the Art Oral Communication Symposium Workshop Master Class Working Group Miscellaneous
1514
Rome Barcelona Sydney Lausanne Seoul Outside the congress platform(by pre-registration)
Ärztlicher Beirat DHGMaster Class 1
Master Class 2
Master Class 3
Symposium Novo Nordisk Pharma GmbH
Symposium Alexion Pharma Germany
GmbH
Symposium CSL Behring GmbH
Cancer-associated Thrombophilia
Cardiology & NeurologyProgress in Hemophilia Treat-
ment
Plenary T&H Across Borders
State of the Art Hemophilia
State of the Art Hemato-Oncology A
State of the Art News on Platelets
State of the Art Cardiology – Neurology
State of the Art Drug Discovery
Symposium Portola FRG GmbH
Symposium LEO Pharma GmbH
Symposium BioMarin Deutschland GmbH
08:00
08:30
09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
17:30
18:00
18:30
19:00
19:30
20:00
20:30
08:00
08:30
09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
17:30
18:00
18:30
19:00
19:30
20:00
20:30
PROGRAM OVERVIEW | TUESDAY, 23.02.2021
Plenary State of the Art Oral Communication Symposium Workshop Master Class Working Group Miscellaneous
1716
Rome Barcelona Sydney Lausanne Seoul Outside the congress platform(by pre-registration)
AG Erworbene HämophilieMaster Class 4
Master Class 5
Master Class 6
Symposium Swedish Orphan Biovitrum
GmbH
Symposium CSL Behring GmbH
Symposium Sanofi
Clinical PracticeCritical Care,
Surgery & Transfusion medicine
New Laboratory Technologies
AG women‘s health
Plenary T&H Across Borders
State of the Art Obstetrics
State of the Art Neurology
State of the Art Coagulation in critical care
State of the Art Hepatology
State of the Art News on Hemostatic Factors
Symposium Bristol-Myers Squibb GmbH & Co. KGaA & Pfizer Pharma
GmbH
Symposium Roche Pharma AG
Symposium Pfizer Pharma GmbH
08:00
08:30
09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
17:30
18:00
18:30
19:00
19:30
20:00
20:30
08:00
08:30
09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
17:30
18:00
18:30
19:00
19:30
20:00
20:30
PROGRAM OVERVIEW | WEDNESDAY, 24.02.2021
Plenary State of the Art Oral Communication Symposium Workshop Master Class Working Group Miscellaneous
1918
Rome Barcelona Sydney Lausanne Seoul Outside the congress platform(by pre-registration)
Master Class 7
Master Class 8
Master Class 9
Master Class 10
Master Class 11
Symposium Swedish Orphan Biovitrum
GmbH
Symposium Takeda Pharma Vertrieb GmbH
& Co. KG
Symposium Bayer Vital GmbH
Symposium Grifols Deutschland GmbH
Mechanisms of Disease IPediatrics & Gynecology-Obs-
tetricsMegakaryocytes, Platelets &
VWF BDDH-Sitzung
Plenary Physicians Across Borders
State of the Art Pediatrics
State of the Art Cardiology
State of the Art Procoagulant Platelets
State of the Art Hemato-Oncology B
State of the Art New treatments
GTH-MV
08:00
08:30
09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
17:30
18:00
18:30
19:00
19:30
20:00
20:30
08:00
08:30
09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
17:30
18:00
18:30
19:00
19:30
20:00
20:30
PROGRAM OVERVIEW | THURSDAY, 25.02.2021
Plenary State of the Art Oral Communication Symposium Workshop Master Class Working Group Miscellaneous
2120
Rome Barcelona Sydney Lausanne Seoul Outside the congress platform(by pre-registration)
Ausstellerbeiratssitzung Master Class 12
Master Class 13
Master Class 14
Symposium Biotest AG
Symposium Sanofi Genzyme
Symposium Siemens Healthcare GmbH
COVID-19Crosstalks between Hemost-
asis and other Systems
Diagnostic laboratory: Today & tomorrow
Mechanisms of Disease II
Plenary Think Across Borders
State of the Art Transfusion medicine
State of the Art Venous Thromboembolism
State of the Art Treatment Challenges
State of the Art Laboratory methods
Closing Ceremony
08:00
08:30
09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
17:30
18:00
18:30
19:00
08:00
08:30
09:00
09:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
16:30
17:00
17:30
18:00
18:30
19:00
PROGRAM OVERVIEW | FRIDAY, 26.02.2021
Plenary State of the Art Oral Communication Symposium Workshop Master Class Working Group Miscellaneous
2322
SCIENTIFIC PROGRAM | MONDAY, 22.02.2021 SCIENTIFIC PROGRAM | MONDAY, 22.02.2021
08:00 – 16:15Rome
MTA & WET-Workshop / BMA-Fallpräsentationen Ständige Kommission
08:00 – 11:30 MTA-Workshop: Hämophilie und ihre Diagnostik
08:00 Hämophilie, ein Überblick Ursachen, Molekulare Mechanismen, GenetikA. Karst (Essen, Germany)
08:30 Grundlagen der primären und sekundären Hämostase unter besonderer Berücksichtigung von F VIII unf F IX Thrombozytenfunktion, Zusammenspiel mit den GerinnungsfaktorenA. Karst (Essen, Germany)
09:30 Kaffeepause
10:00 Therapiekonzepte Substitution, GentherapieB. Schuster (Essen, Germany)
10:15 Hämophilie im GerinnungslaborDiagnostik der Hämophilie, Monitoring der Therapie, Diagnostik der FaktoreninhibitorenB. Schuster (Essen, Germany)
11:30 Mittagspause
12:30 – 14:00 WET-Workshop der STAEKOLA
12:30 Evaluation der Leistungsfähigkeit des Atellica COAG 360 in einem ZentrallaborS. Hörber (Tübingen, Germany)
13:00 Halbwertszeit-verlängerten FaktorenkonzentratenJ. Müller (Bonn, Germany)
13:30 Labordiagnostik bei Hämophilie A-Patienten unter Therapie mit EmicizumabU. Sachs (Giessen, Germany)
14:00 Kaffeepause
14:30 – 16:15 BMA-Fallpräsentationen
14:30 Multiplate A. Gähler (Luzern, Switzerland), M. Riedweg (Luzern, Switzerland)
14:55 Fallbeispiele DIC/HELLP M. Martinez (Basel, Switzerland), S. Lichtenthäler (Basel, Switzerland)
15:20 Verlängerte aPTT L. Graf (St. Gallen, Switzerland), S. Niggli (St. Gallen, Switzerland)
15:45 Faktor XI-Mangel J-D. Studt (Zurich, Switzerland)
10:00 – 11:00 Master ClassChoice of anticoagulation in the general cardiac patientsTutor: J. Steffel (Zurich, Switzerland)
10:00 – 11:00 Master ClassFlow-based assays to study platelet function, hemostasis and thrombosisTutor: P. Mangin (Strasbourg, France)
13:00 – 17:00Lausanne
Treffen der Hämostaseologie-AssistentInnen
13:00 BegrüßungI. Haferland (Frankfurt, Germany), S. Halimeh (Duisburg, Germany)
13:10 Refresher Thrombophilie im KindesalterS. Halimeh (Duisburg, Germany), M. Olivieri (Munich, Germany)
Refresher Thrombophilie im ErwachsenenalterM. Krause (Wiesbaden, Germany)
14:00 Pause
14:10 Gentherapie bei Hämophilie AR. Klamroth (Berlin, Germany)
15:00 Pause
15:10 Patientenmanagement in Pandemiezeiten – Was macht das mit UNS???S. von Mackensen (Hamburg, Germany)
16:20 Pause
16:30 Aktuelle Entwicklung des Arbeitskreises der Hämostaseologie-AssistentInnenI. Haferland (Frankfurt, Germany)
Stand „Strukturierte Patientenschulung“J. Rehlig (Dresden, Germany)
Stand „Pflegeforschungsprojekt“J. Ruthenberg (Berlin, Germany)
Verschiedenes
13:30 – 14:30Sydney
Ständige Kommission Pädiatrie
15:00 – 16:00 Sydney
Ständige Kommission Hämophilie
16:30 – 17:30 Rome
Ständige Kommission Labor
24
SCIENTIFIC PROGRAM | MONDAY, 22.02.2021
18:00 – 20:30 Rome
Opening Ceremony
18:00 Introduction L. Alberio (Lausanne, Switzerland)
18:05 Welcome Address J. Oldenburg (Bonn, Germany)
18:15 Welcome Address L. Alberio (Lausanne, Switzerland)
18:25 Welcome Address J-D. Tissot, Faculty of Biology and Medicine, UNIL (Lausanne, Switzerland)
18:35 GTH awards TBD
18:50 Across Borders Online
19:10 Alexander Schmidt Lecture M. Bender (Würzburg, Germany)
19:30 Key note lecture «Per aspera ad astra» C. Nicollier (Lausanne, Switzerland)
19:50 Closing L. Alberio (Lausanne, Switzerland)
20:00 Across Borders Online
Platzhalter Inserat
2726
SCIENTIFIC PROGRAM | TUESDAY, 23.02.2021 SCIENTIFIC PROGRAM | TUESDAY, 23.02.2021
09:00 – 10:30Rome
Ärztlicher Beirat DHG
09:00 – 10:00 Master ClassHemostasis in critical careTutor: W. Korte (St. Gallen, Switzerland)
10:00 – 11:00 Master ClassLab testing of anticoagulants in everyday practiceTutor: I. Gouin-Thibault (Rennes, France), F. Mullier (Yvoir, Belgium)
11:00 – 12:00 Master ClassDiagnosis of venous thromboembolic diseaseTutor: M. Righini (Geneva, Switzerland)
12:00 – 13:30Rome
Satellite Symposium Novo NordiskVII – VIII – IX – Klinische Entscheidungen beruhen auf Erfahrungen. Das Symposium mit ErfahrungsaustauschChairs: I. Hegemann (Zurich, Switzerland), C. Escuriola-Ettingshausen (Mörfelden-Walldorf, Germany)
12:00 Entscheidung für N8-GP oder N9-GP bei Kindern: Erfahrungen aus der Schweiz*H. Hengartner (St. Gallen, Switzerland)
12:30 Erfahrung entscheidet: N8-GP und N9-GP bei chirurgischen Eingriffen G. Goldmann (Bonn, Germany)
13:00 Sicher entscheiden bei erworbener Hämophilie: Neue Empfehlungen und Daten A. Tiede (Hannover, Germany)
12:00 – 13:30Barcelona
Satellite Symposium Alexion Pharma Germany GmbHThrombosen und thrombotische Mikroangiopathien – wenn das Komplement sich einmischt Chair: F. Langer (Hamburg, Germany)
12:00 Thrombozytopenie mit Hämolyse und Nierenbeteiligung – wann an aHUS denken?T. Feldkamp (Hannoversch Münden, Germany)
12:20 Seltene Thrombosen, schon mal an PNH gedacht? F. Langer (Hamburg, Germany)
12:40 Ravulizumab-Reloaded: Die C5-Komplementinhibition geht in die nächste Runde! A. Röth (Essen, Germany)
13:00 Diskussion
12:00 – 13:30Sydney
Satellite Symposium CSL Behring GmbHGerinnung bleibt spannend – von Covid-19 zur Gentherapie Chair: K. Kurnik (Munich, Germany)
12:00 Covid-19 und Gerinnungsstörungen: Hämophilie/VWSF. Langer (Hamburg, Germany)
12:20 AFSTYLA – eine lang wirksame Option in der Hämophilie A (MAIC – Daten) M. Olivieri (Munich, Germany)
12:35 IDELVION – neue klinische Daten J. Oldenburg (Bonn, Germany)
12:50 Kasuistiken AFSTYLA K. Dengler (Bremen, Germany), G. Goldmann (Bonn, Germany)
13:10 Gentherapie in der Hämophilie B R. Klamroth (Berlin, Germany)
13:25 Diskussion
13:45 – 15:00Rome
Oral CommunicationsCancer-associated ThrombophiliaChairs: J-D. Studt (Zurich, Switzerland), C. Frère (Paris, France)
13:45 Development and validation of machine learning predictive models applying for cancer-associated deep vein thrombosis: A 1035-sample retrospective cohort studyS. Jin, D. Qin, B. S. Liang, L. C. Zhang, X. X. Wei, Y. J. Wang, B. Zhuang, T. Zhang, Z. P. Yang, Y. W. Cao, S. L. Jin, P. Yang, B. Jiang, B. Q. Rao, H. P. Shi, Q. Lu (Beijing, China)
13:55 Modelization the impact of antithrombotic agents on pancreatic tumoral micro-environment. H. Tran1, R. Amrane1, E. Mbemba1, M. Sabbah1, P. Vandreden2, 1, G. Gerotziafas1 (1Paris, France, 2Gennevilliers, France)
14:05 Aggressiveness of breast cancer cells is related with tissue factor expression and procoagulant activity. E. Mbemba1, R. Amrane1, N. Ferrand1, M. Sabbah1, P. Vandreden1, 2, G. Gerotziafas1 (1Paris, France, 2Genevilliers, France)
14:15 LMWH or DOACs for cancer associated thrombosis (CAT) in daily clinical practice ? – Insights from the GECAT registry R. Klamroth1, C. Pollich1, H. Riess1, M. Sinn2 (1Berlin, Germany, 2Hamburg, Germa-ny)
14:25 Anticoagulation practice of cancer-associated thrombosis in the outpatient sector of Germany H. Riess1, A. Kretzschmar2, A. Heinken3, D. Mohebi4, M. May4, S. Schellong5 (1Berlin, Germany, 2Leipzig, Germany, 3Munich, Germany, 4Düsseldorf, Germany, 5Dresden, Germany)
14:35 Q&A* N8-GP und N9-GP sind im Geltungsbereich der Zentralen Europäischen Zulassung (u.a. Deutschland und Österreich) für Patienten im Alter von 12 Jahren und älter zugelassen. In der Schweiz sind N8-GP und N9-GP für vorbehandelte Patienten ab 0 Jahren zugelassen.
2928
13:45 – 15:15Barcelona
Oral CommunicationsCardiology & NeurologyChairs: C. Herrera Siklódy (Lausanne, Switzerland), L. Hirt (Lausanne, Switzerland)
13:45 Current status of anti-thrombotic therapy in patients with atrial fibrillation undergoing PCI. Results of the prospective RIVA-PCI Registry.U. Zeymer (Ludwigshafen, Germany)
13:55 Anticoagulation for stroke prevention in patients with atrial fibrillation on hemodialysis is associated with net-clinical harm O. Königsbrügge1, H. Meisel1, S. Schmaldienst1, R. Klauser-Braun1, M. Lorenz1, M. Auinger1, J. Kletzmayr1, M. Hecking1, W. Winkelmayer2, I. Lang1, I. Pabinger1, M. Säemann1, C. Ay1 (1Vienna, Austria, 2Houston, United States)
14:05 Red Cell Omega-3 FA Correlate with Reduced DDimer and Beta-Thrombo-globulin as Markers of Coagulation Activation in Atrial Fibrillation D. A. Bertschi1, M. F. Reiner1, J. Rutishauser1, S. S. Saeedi2, L. Werlen3, S. Aeschbacher3, S. Osswald3, D. Conen3, 4, J. H. Beer1, 2 (1Baden, Switzerland, 2Schlieren, Switzerland, 3Basel, Switzerland, 4Hamilton, Canada)
14:15 Growth differentiation factor-15 predicts major cardiac adverse events and all-cause mortality in patients with atrial fibrillationS. Nopp, O. Königsbrügge, D. Kraemmer, I. Pabinger, C. Ay (Vienna, Austria)
14:25 Regulation of platelet counts after myocardial ischemia and reperfusion injury B. Tajdar, M. Klier, F. Reusswig, M. Elvers (Düsseldorf, Germany)
14:35 Intracranial involvement and neurologic manifestations in Lemierre syndrome: analysis of 712 patients. L. Valerio1, T. F. Nicoletti2, G. P. Corsi3, S. Granziera4, M. Jankowski1, A. Pecci5, C. Sacco6, F. Zane7, S. V. Konstantinides1, 8, S. Barco1, 9 (1Mainz, Germany, 2Rome, Italy, 3Bologna, Italy, 4Mestre, Italy, 5Pavia, Italy, 6Rozzano, Italy, 7Sondrio, Italy, 8Alexandroupolis, Greece, 9Zurich, Switzerland)
14:45 Q&A
13:45 – 15:15Sydney
Oral CommunicationsProgress in Hemophilia TreatmentChairs: R. Klamroth (Berlin, Germany), M. Martinez (Basel, Switzerland)
13:45 AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophi-lia B Confirms Stable FIX Expression and Sustained Reductions in Bleeding for up to 5 YearsW. A. Miesbach1, K. Meijer2, M. Coppens3, P. Kampmann4, R. Klamroth5, R. Schutgens6, G. Castaman7, E. Seifried8, J. Schwaeble8, H. Bönig9, E. K. Sawyer10, F. Leebeek11 (1Frankfurt am Main, 2Groningen, 3Amsterdam, 4Copenhagen, 5Berlin, 6Utrecht, 7Florence, 8Wurttemberg-Hessen, 9Seattle, 10Lexington, 11Rotterdam)
13:55 Gene Transfer with Etranacogene dezaparvovec (AAV5-Padua hFIX variant) in Adults with Severe or Moderate-Severe Hemophilia B: Two Year Data from a Phase 2b Trial W. A. Miesbach1, A. Giermasz2, G. Castaman3, N. S. Key4, S. U. Lattimore5, F. Leebeek6, A. von Drygalski7, M. Recht5, E. Gomez8, R. Gut9, S. W. Pipe10 (1Frankfurt am Main, 2Sacramento, 3Florence, 4Chapel Hill, 5Portland, 6Rotterdam, 7La Jolla, 8Phoenix, 9Lexington, 10Ann Arbor)
14:05 The Innovative Factor VIII Molecules HAT and HAT RI Overcome Impair-ments of Hemophilia A Therapy P. Herbener, J. Daufenbach, K. Winterling, J. Schüttrumpf, S. Kistner (Dreieich)
14:15 Long-term Efficacy and Safety of Fitusiran in Participants with Hemophilia A and B: An Interim Analysis of the Phase 1/2 Open-Label Extension StudyC. Négrier1, M. V. Ragni2, K. J. Pasi3, S. W. Pipe4, I. Hegemann5, P. Chowdary3, T. Lissitchkov6, P. Georgiev7, Z. Qiu8, S. Poloskey8, S. Kichou9, B. Mei9, S. Andersson9, C. Sussebach10 (1Lyon, 2Pittsburgh, 3London, 4Michigan, 5Zurich, 6Sofia, 7Plovdiv, 8New Jersey, 9Massachusetts, 10Germany)
14:25 Treatment with Eptacog Beta (Factor VIIa, Recombinant) Results in Early Bleed Resolution for Persons with Hemophilia A or B with Inhibitors: Results of the randomized cross-over PERSEPT 1 phase 3 study C. Hermans1, W. Miesbach2, M. Wang3, J. Ducore4, J. Journeycake5, M. Escobar6, D. Quon7, L. Boggio8, I. S. Mitchell9, A. Al-Sabbagh10, D. Bonzo10, W. A. Alexander11, J. Mahlangu12 (1Brussels, 2Frankfurt, 3Aurora, Co, 4Sacramento, 5Oklahoma, 6Houston, TX, 7Los Angeles, Ca, 8Chicago, IL, 9Broomfield, CO, 10Framingham, MA, 11Loiusville, KY, 12Johannesburg)
14:35 Second interim analysis results from the STASEY trial: A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of emicizumab prophylaxis in persons with haemophilia A (PwHA) with FVIII inhibitors V. Jiménez-Yuste1, R. Klamroth2, G. Castaman3, J. Kremer Hovinga4, C. Shanmukhaiah5, S. Rangarajan5, J. García Chavez6, R. Martinez6, G. Kenet7, S. Robson8, C. Schmitt8, O. Meier8, M. Ozelo9 (1Madrid, 2Berlin, 3Florence, 4Bern, 5Mumbai, 6Mexico City, 7Ramat Gan, 8Basel, 9São Paulo)
14:45 Q&A
15:30 – 16:30Rome
PlenaryT&H Across BordersChairs: TBD
15:30 Recent advances in gene therapyK. High (Pennsylvania, United States)
16:00 New opportunities for diagnosis and prognosis of stroke: the benefits of across border approaches D. Vivien (Caen, France)
SCIENTIFIC PROGRAM | TUESDAY, 23.02.2021 SCIENTIFIC PROGRAM | TUESDAY, 23.02.2021
3130
16:45 – 18:15Rome
State of the ArtHemophiliaChairs: I. Hegemann (Zurich, Switzerland), M. Olivieri (Munich, Germany)
16:45 Modern treatment of hemophilia in childrenM. Carcao (Toronto, Canada)
17:05 How to deal with inhibitors A. Tiede (Hannover, Germany)
17:25 Patient-tailored hemophilia treatmentC. Négrier (Lyon, France)
17:45 Q&A
16:45 – 18:15Barcelona
State of the ArtHemato-oncology AChairs: B. Gerber (Bellinzona, Switzerland), M. Voigtländer (Hamburg, Germany)
16:45 Hemostatic markers and prognosis in patients with cancerI. Pabinger-Fasching (Vienna, Austria)
17:05 Primary thromboprophylaxis in ambulatory cancer patients A. Khorana (Cleveland, United States)
17:25 Management of disseminated intravascular coagulation in leukemiaH. ten Cate (Maastricht, Netherlands)
17:45 Q&A
16:45 – 18:15Sydney
State of the ArtNews on PlateletsChairs: B. Zieger (Freiburg im Breisgau, Germany), B. Kehrel (Münster, Germany)
16:45 Modulating platelet reactivity by the crosstalk of protein kinase and phosphatase signaling pathwaysK. Jurk (Mainz, Germany)
17:05 Regulation of platelet function by microRNAs P. Fontana (Geneva, Switzerland)
17:25 Platelets and matrix metalloproteinases: a complex interaction with multiple physiologic and pathologic implicationsP. Gresele (Perugia, Italy)
17:45 Q&A
SCIENTIFIC PROGRAM | TUESDAY, 23.02.2021 SCIENTIFIC PROGRAM | TUESDAY, 23.02.2021
16:45 – 18:15Lausanne
State of the ArtCardiology – NeurologyChairs: P. Michel (Lausanne, Switzerland), J. Steffel (Zurich, Switzerland)
16:45 DOACs in atrial arrhytmias: Current state of the art J. Beyer-Westendorf (Dresden, Germany)
17:05 DOACs after ischemic stroke: Which patient? Which drug? And how early? G. M. De Marchis (Basel, Switzerland)
17:25 Reversing DOACs: Possibilities and usefulness S. Eichinger-Hasenauer (Vienna, Austria)
17:45 Q&A
16:45 – 18:15Seoul
State of the ArtDrug discoveryChairs: Ch. Heinis (Lausanne, Switzerland), TBD
16:45 Therapeutics from snake venoms R. M. Kini (Singapore)
17:05 Q&A
17:15 Biomolecules-derived drugs TBD
17:35 Chasing new therapeutics Th. Szucs (Basel, Switzerland)
17:55 Q&A
18:30 – 20:00Rome
Satellite Symposium PortolaNew Perspective for Reversal of Anticoagulation in Factor Xa Inhibitor-asso-ciated BleedingChair: C. Ay (Vienna, Austria)
18:30 Welcome & Introduction C. Ay (Vienna, Austria)
18:40 Management of Factor Xa inhibitor-associated life-threatening bleeding – current evidence E. Lindhoff-Last (Frankfurt am Main, Germany)
19:00 Activity of Factor Xa inhibitors – how to test and rate correctly? W. Korte (St. Gallen, Switzerland)
19:20 Andexanet alfa – case presentation and insights from practical use I. Pabinger-Fasching (Vienna, Austria)
19:40 Discussion C. Ay (Vienna, Austria)
3332
18:30 – 20:00Barcelona
Satellite Symposium LEO Pharma GmbHThrombosemanagement bei Patienten mit GI-, GU- und Gyn-Tumoren („3G“) aus onkologischer SichtChair: F. Langer (Hamburg, Germany)
18:30 Abwägungen in der Therapieentscheidung aus Sicht des Hämostaseologen: Der CAT-Behandlungsalgorithmus F. Langer (Hamburg, Germany)
18:45 Herausforderung aus Sicht des Onkologen für die Behandlung von Tumor & Thrombose – bei gastro-onkologischen Patienten R-D. Hofheinz (Mannheim, Germany)
19:05 Herausforderung aus Sicht des Onkologen für die Behandlung von Tumor & Thrombose – bei uro-onkologischen Patienten A. S. Merseburger (Lübeck, Germany)
19:25 Herausforderung aus Sicht des Onkologen für die Behandlung von Tumor & Thrombose – bei gyn-onkologischen Patienten H-J. Lück (Hannover, Germany)
19:45 Therapie und Thromboseprophylaxe onkologischer Patienten für den klinischen Alltag F. Langer (Hamburg, Germany)
18:30 – 20:00Sydney
Satellite Symposium BioMarin Deutschland GmbHGene therapy – What do I need to know?Chair: J. Oldenburg (Bonn, Germany)
18:30 Opening J. Oldenburg (Bonn, Germany)
18:35 What’s new in clinical trials? K. J. Pasi (London, United Kingdom)
18:48 What happens in the liver? S. Fong (San Rafael, United States)
19:01 What does the patient need to know? – Facts and emotion S. von Mackensen (Hamburg, Germany)
19:14 What is the patients’ experience? W. Miesbach (Frankfurt am Main, Germany)
19:27 What does that mean for me? R. Klamroth (Berlin, Germany)
19:40 Panel discussion
SCIENTIFIC PROGRAM | TUESDAY, 23.02.2021 SCIENTIFIC PROGRAM | WEDNESDAY, 24.02.2021
09:00 – 10:30Rome
AG Erworbene Hämophilie
09:00 – 10:00 Master ClassPoint-of-Care Platelet Function test in Cariac SurgeryTutor: G. Casso (Lugano, Switzerland), C. Marcucci (Lausanne, Switzerland)
10:00 – 11:00 Master ClassTranslating diagnostic tests and predictive biomarkers into clinical practiceTutor: M. Nagler (Bern, Switzerland)
11:00 – 12:00 Master ClassHow to design a clinical research project?Tutor: M. Valgimigli (Lugano, Switzerland)
12:00 – 13:30Rome
Satellite Symposium Swedish Orphan Biovitrum GmbHAcross AgesChairs: J. A. Kremer Hovinga (Bern, Switzerland), I. Pabinger-Fasching (Vienna, Austria)
12:00 Einführung: rFVIIIFc im Leben eines Hämophilie-A-Patienten
12:05 Der Start ins Leben… Ch. Königs (Frankfurt am Main, Germany)
12:15 Wenn doch etwas schief läuft… R. Knöfler (Dresden, Germany)
12:25 Im Alltag… A. Tiede (Hannover, Germany)
12:35 Über längere Zeit… J. Oldenburg (Bonn, Germany)
12:45 Für außergewöhnliche Situationen… I. Pabinger-Fasching (Vienna, Austria)
12:55 Bis ins hohe Alter… J. A. Kremer Hovinga (Bern, Switzerland)
13:05 Wohin die Zukunft geht… R. Klamroth (Berlin, Germany)
13:15 Q&A
3534
12:00 – 13:30Barcelona
Satellite Symposium CSL Behring GmbH40 Jahre: bewährt. bewährter. Haemate - für jeden TypChair: W. Eberl (Braunschweig, Germany)
12:00 Zeiten ändern sich, Werte bleiben C. Escuriola-Ettingshausen (Mörfelden-Walldorf, Germany), S. Halimeh (Duis-burg, Germany), W-A. Hassenpflug (Hamburg, Germany), Ch. Pfrepper (Leipzig, Germany)
12:30 Resumé aus >25.000 Patientenjahren: gestern und heute I. Pabinger-Fasching (Vienna, Austria)
12:50 Behandlung primärer oder sekundärer Sterilität bei Patientinnen mit vWS B. Krammer-Steiner (Rostock, Germany)
13:10 Erworbenes vWS bei Patienten mit VAD, ECLS oder ECMO B. Zieger (Freiburg im Breisgau, Germany)
12:00 – 13:30Sydney
Satellite Symposium SanofiAntikoagulation bei internistischen Patienten – FallbeispieleChair: B. Gerber (Bellinzona, Switzerland)
12:00 Primärprophylaxe bei Tumorpatienten: State-of-the-Art und Kontroversen W. Korte (St. Gallen, Switzerland)
12:30 Thrombose-Prophylaxe bei intensiv-medizinischen Patienten: Was haben wir in der COVID-19 Pandemie gelernt? B. Linnemann (Regensburg, Germany)
13:00 Thrombose-Prophylaxe nach dem Spitalaustritt: Bei wem und wie lange? C. Ay (Vienna, Austria)
13:45 – 15:00Rome
Oral CommunicationsClinical PracticeChairs: G. Colucci (Lugano, Switzerland), Ch. von Auer (Mainz, Germany)
13:45 Efficacy and Safety of Human Fibrinogen Concentrate in Patients with Congenital Fibrinogen Deficiency: Combined Results of the FORMA-02 and FORMA-04 Clinical Trials C. Djambas Khayat1, S. Lohade2, F. D‘Souza3, L. S. Gowda4, O. Zekavat5, I. Kruzhkova6, B. Schwartz7, C. Solomon6, F. Peyvandi8 (1Beirut, 2Pune, 3Bangalore, 4Davangere, 5Shiraz, 6Lachen, 7New Jersey, 8Milan)
13:55 Treatment of immune thrombocytopenia (ITP) with Eltrombopag – results of the 3rd interim analysis of the German non-interventional trial RISA. Focussing on steroid-pretreatment and fatigue O. Meyer1, D. Kämpfe2, R. Schlag3, M. Reiser4, E. von der Heyde5, A. Josting1, M. Plath6, N. Ballerstädt7, P. Stark-Lorenzen7, M. Stauch8 (1Berlin, 2Lüdenscheid, 3Würzburg, 4Cologne, 5Hannover, 6Augsburg, 7Nuremberg, 8Kronach)
14:05 Acquired Hemophilia A (AHA) Limits of the Awareness Push in Germany S. Wahler1, A. Tiede2 (1Hamburg, 2Hannover)
14:15 Pain status in patients with hemophilia: evaluation of routine pain assessment in an unselected cohort of patients with hemophilia A and B K. Holstein, K. Veltrup, M. Tetzlaff, G. Schröder, S. von Mackensen, F. Langer (Hamburg)
14:25 Safety and efficacy of a high-purity plasma derived von Willebrand Factor in patients with von Willebrand disease (VWD) undergoing prophylaxis for joint bleeding: results from a post-marketing study J. Goudemand1, A. Borel-Derlon2, B. Müller-Plettenberg3, C. Henriet4 (1Lille, 2Caen, 3Münster, 4Les Ulis)
14:35 Q&A
13:45 – 15:15Barcelona
Oral CommunicationsCritical Care, Surgery & Transfusion medicineChairs: E. Scala (Lausanne, Switzerland), TBD
13:45 Prevalence and clinical impact of reduced FXII activity in patients receiving extracorporeal membrane oxygenation N. Buchtele, M. Schwameis, C. Schoergenhofer, P. Knöbl, B. Jilma, P. Quehenberger, T. Staudinger (Vienna)
13:55 Assessment of the anticoagulant effect of direct oral anticoagulants (DOACs) in patients needing immediate management during emergency procedures M. Caspers, S. Roeschl, J. Holle, H. Bendella (Cologne)
14:05 Implementation of Direct Oral Anticoagulant (DOAC) Perioperative Interrupti-on and Interval evaluation of the DOASENSE Dipstick performance L. H. Paz Rios1, J. Harenberg2, J. M. Walenga3, T. Gniadek1, J. Fareed3, A. J. Tafur1 (1Evanston, 2Heidelberg, 3Maywood)
14:15 Von Willebrand factor ratio as a risk factor for bleeding in aortic valve stenosis replacement surgery M. Wolny1, C. Brandenburger1, V. Unislawski1, U. Budde2, A. Zittermann1, J. Gummert1, T. Flieder1, K. von Bargen1, F. Knüttgen1, C. Knabbe1, I. Birschmann1 (1Bad Oeynhausen, 2Hamburg)
14:25 Safety and efficacy of a high-purity plasma-derived von Willebrand Factor in patients with von Willebrand disease (VWD) undergoing prophylaxis for gastrointestinal bleeding: results from a post-marketing study J. Goudemand1, A. Borel-Derlon2, B. Müller-Plettenberg3, C. Henriet4 (1Lille, 2Caen, 3Münster, 4Les Ulis)
14:35 Removal of citrate from PAS-III additive solution improves functional and biochemical characteristics of buffy-coat platelet concentrates stored for seven days, with or without Intercept pathogen reduction H. Isola, C. Ravanat, F. Rudwill, A. Pongérard, D. Haas, A. Eckly, C. Gachet, B. Hechler (Strasbourg)
14:45 Q&A
SCIENTIFIC PROGRAM | WEDNESDAY, 24.02.2021 SCIENTIFIC PROGRAM | WEDNESDAY, 24.02.2021
3736
SCIENTIFIC PROGRAM | WEDNESDAY, 24.02.2021 SCIENTIFIC PROGRAM | WEDNESDAY, 24.02.2021
13:45 – 15:15Sydney
Oral CommunicationsNew Laboratory TechnologiesChairs: W. Korte (St. Gallen, Switzerland), P. Jilma (Vienna, Austria)
13:45 Diagnosis of inherited platelet disorders: comparison between immunoflu-orescence analysis on the blood smear and genetic testing C. Zaninetti1, 2, J. Rivera3, E. Leinoe4, M. Wolff1, C. Freyer1, A. Greinacher1 (1Greifswald, 2Pavia, 3Murcia, 4Copenhagen)
13:55 Next-generation sequencing identified different types of Hermansky-Pudlak syndrome associated with phenotype variability D. Boeckelmann, H. Glonnegger, F. Sobotta, F. Andresen, A. Lenz, S. Fels, B. Zieger (Freiburg)
14:05 In-vivo model to assess platelet age in humans: during increased platelet turnover large and small platelets are produced simultaneously M. Wolff, S. Handtke, A. Greinacher, T. Thiele (Greifswald)
14:15 Assessment of primary hemostasis with an acoustic biosensor using shear dependent kinetics behavior: principle and limitations A. Oseev1, N. Mukhin2, F. Remy-Martin1, C. Elie-Caille1, T. Lecompte3, G. Mourey1, A. Rouleau1, O. Bourgeois1, B. Le Roy de Boiseaumarié1, E. de Maistre4, R. Lucklum2, W. Boireau1, F. Chollet1, J.-F. Manceau1, T. Leblois1 (1Besançon, 2Magdeburg, 3Geneva, 4Dijon)
14:25 Aptamer-based ex vivo monitoring of thrombin and activated protein C ge-neration on blood outgrowth endothelial cells for individualized assessment of the protein C pathway N. Schwarz, J. Müller, J. Oldenburg, B. Pötzsch, H. Rühl (Bonn)
14:35 Human platelets labeled at two discrete biotin densities are functional in vi-tro and are detected in vivo in the mouse circulation. A promising approach to monitor in vivo platelet survival in clinical research C. Ravanat, A. Pongérard, M. Freund, V. Heim, F. Rudwill, C. Ziessel, A. Eckly, F. Proamer, H. Isola, C. Gachet (Strasbourg)
14:45 Q&A
14:15 – 15:30Lausanne
AG women‘s health
15:30 – 16:30Rome
PlenaryT&H Across BordersChairs: M-Ch. Alessi (Marseille, France)
15:30 Platelets beyond thrombosisS. Massberg (Munich, Germany)
16:00 Hemostasis in Hibernation O. Frøbert (Örebro, Sweden)
16:45 – 18:15Rome
State of the ArtObstetrics-Cardiology Chairs: T. Rutz (Lausanne, Switzerland), D. Baud (Lausanne, Switzerland)
16:45 How to approach atrial arrhytmias during pregnancy V. Regitz-Zagrosek (Berlin, Germany)
17:05 How to approach venous thromboembolism during pregnancy L. Mazzolai (Lausanne, Switzerland)
17:25 How to anticoagulate pregnant women with prosthetic valves J. Roos-Hesselink (Rotterdam, Netherlands)
17:45 Q&A
16:45 – 18:15Barcelona
State of the ArtNeurologyChairs: U. Fischer (Bern, Switzerland), D. Aguiar de Sousa (Lisbon, Portugal)
16:45 Mechanisms of clot formation and resolution I. Lang (Vienna, Austria)
17:05 Thrombolytics, clots and neurons: a two-edged sword L. Hirt (Lausanne, Switzerland)
17:25 Sinus venous thrombosis: What's new? D. Aguiar de Sousa (Lisbon, Portugal)
17:45 Q&A
16:45 – 18:15Sydney
State of the ArtCoagulation in critical careChairs: TBD, TBD
16:45 Current concepts on pathophysiology and treatment of trauma-induced massive hemorrhage A. P. Cap (Houston, United States)
17:05 Cardiac surgery in heparin-induced thrombocytopenia E. Scala (Lausanne, Switzerland)
17:25 Managing coagulation in the setting of cardiac assist devices in children and adults S. Susen (Lille, France)
17:45 Q&A
3938
SCIENTIFIC PROGRAM | WEDNESDAY, 24.02.2021 SCIENTIFIC PROGRAM | WEDNESDAY, 24.02.2021
16:45 – 18:15Lausanne
State of the ArtHepatologyChairs: A. De Gottardi (Bellinzona, Switzerland),V. Hernandez-Gea (Barcelona, Spain)
16:45 Current concepts on the pathophysiolgy of coagulation in liver cirrhosis T. Lisman (Groningen, Netherlands)
17:05 Management of anticoagulation in cirrhotic patients E. Villa (Modena, Italy)
17:25 Invasive procedures in patients with impaired hemostasis due to liver cirrhosis W. Bernal (London, United Kingdom)
17:45 Q&A
16:45 – 18:15Seoul
State of the ArtNews on hemostatic factorsChairs: J. A. Kremer Hovinga (Bern, Switzerland), K. Kurnik (Munich, Germany)
16:45 VWF propeptide D. Lillicrap (Kingston, Canada)
17:05 Coagulation factor XI J. Emsley (Nottingham, United Kingdom)
17:25 Polyphosphates in platelets and beyond Th. Renné (Hamburg, Germany)
17:45 Q&A
18:30 – 20:00Rome
Satellite Symposium Bristol-Myers Squibb GmbH & Co. KGaA / Pfizer Pharma GmbHCancer-associated Thrombosis: Evidence – Recommendations – ExperienceChairs: L. Mazzolai (Lausanne, Switzerland), S. Konstantinides (Mainz, Germany)
18:30 CARAVAGGIO – New Data on oral Anticoagulation in Cancer-associated Thrombosis M. Huisman (Leiden, Netherlands)
18:55 Cancer-associated Thrombosis: What the Guidelines can tell you H. Riess (Berlin, Germany)
19:20 A complex case of Cancer-associated Thrombosis: What the Guidelines can’t tell you F. Langer (Hamburg, Germany)
19:45 Discussion, Q&As
18:30 – 20:00Barcelona
Satellite Symposium Roche Pharma AG / Chugai Pharma Germany GmbHEmicizumab‘s impact on patients‘ livesChair: R. Klamroth (Berlin, Germany)
18:30 Welcome and Long-Term Efficacy & Safety of Emicizumab in HAVEN 1-4 R. Klamroth (Berlin, Germany)
18:45 Case Reports of Patients Treated with Emicizumab and Its Impact on Their Lives Ch. Hay (Manchester, United Kingdom)
19:00 Case Reports of Patients Treated with Emicizumab and Its Impact on Their Lives M. Rizzi (Lausanne, Switzerland)
19:15 Case Reports of Patients Treated with Emicizumab and Its Impact on Their Lives Ch. Pfrepper (Leipzig, Germany)
19:30 Panel Discussion
19:45 Live-Q&A
18:30 – 20:00Sydney
Satellite Symposium Pfizer Pharma GmbHHämophilie-Therapien von morgen: Erfahrungen und Herausforderungen aus dem StudienalltagChair: A. Tiede (Hannover, Germany)
18:30 Gentherapien für Erwachsene – Besonderheiten bei der Beratung, Durchführung und Nachsorge J. Oldenburg (Bonn, Germany)
19:00 Gentherapien für Kinder – Was ist hier anders? M. Olivieri (Munich, Germany)
19:30 Anti-TFPI Therapie – Eine gut geeignete Alternative?K. Holstein (Hamburg, Germany)
4140
08:30 – 09:30 Master ClassCOVID-19 & hemostasisTutor: Th. Lecompte (Geneva, Switzerland)
09:00 – 10:00 Master ClassHow I treat chronic ITP in childrenTutor: N. von der Weid (Basel, Switzerland)
10:00 – 11:00 Master ClassHow I approach anemia in childrenTutor: M. Schmugge (Zurich, Switzerland)
11:00 – 12:00 Master ClassInterprofessional approach of joint health in pediatric haemophiliaTutor: M. Albisetti (Zurich, Switzerland), D. Etzweiler (Zurich, Switzerland)
11:00 – 12:00 Master ClassEmicizumab & Coagulation labTutor: P. Fontana (Geneva, Switzerland)
12:00 – 13:30Rome
Satellite Symposium Swedish Orphan Biovitrum AB / Florio GmbHTake control – harness the power of data to aim higherChair: L. Graf (St. Gallen, Switzerland)
12:00 Begrüßung L. Graf (St. Gallen, Switzerland)
12:15 Medical Devices in Haemophilia: Erwartungen eines Arztes und eines Patienten C. Escuriola-Ettingshausen (Mörfelden-Walldorf, Germany)
12:45 Patient self-empowerment: gemeinsam personalisierte Ziele erreichen G. Goldmann (Bonn, Germany)
13:15 Diskussion
12:00 – 13:30Barcelona
Satellite Symposium Takeda Pharma Vertrieb GmbH & Co. KGPersonalisierte Therapie – eine neue Ära in der Behandlung von BlutgerinnungsstörungenChair: I. Pabinger-Fasching (Vienna, Austria)
12:00 PK-gesteuerte Prophylaxe – eine therapeutische Strategie zur Erhaltung der Gelenkgesundheit R. Klamroth (Berlin, Germany)
12:30 Das Von-Willebrand-Syndrom - der personalisierte Therapieansatz mit dem rVWF M. Spannagl (Munich, Germany)
13:00 Schritte zur Präzisionsmedizin in der personalisierten Therapie P. Turecek (Vienna, Austria)
12:00 – 13:30Sydney
Satellite Symposium Bayer Vital GmbHGrenzen überwinden – Protektive Strategien bei Thrombosen und HämophilieChairs: B. Kemkes-Matthes (Giessen, Germany), E. Lindhoff-Last (Frankfurt am Main, Germany)
12:00 Begrüßung B. Kemkes-Matthes (Giessen, Germany)
12:05 VTE-Patienten behandeln und schützen – Thrombosen therapieren und Rezidive vermeiden R. M. Bauersachs (Darmstadt, Germany)
12:25 Leitlinienempfehlungen und Patientenwunsch – Strategien zum Therapieerfolg bei tumorassoziierter Thrombembolie C. Ay (Vienna, Austria)
12:45 Hämophilie A - Neue Guidelines & EHLs topaktuell A. Tiede (Hannover, Germany)
13:05 Ask-the-Expert
13:25 Zusammenfassung E. Lindhoff-Last (Frankfurt am Main, Germany)
12:00 – 13:30Lausanne
Satellite Symposium Grifols Deutschland GmbHFostamatinib – die neue Therapie bei chronischer ITP ab der ZweitlinieChair: A. Matzdorff (Berlin, Germany)
12:00 Einleitung A. Matzdorff (Berlin, Germany)
12:05 Leitlinien-Update & besondere Aspekte der ITP-Therapie unter Covid-19 A. Matzdorff (Berlin, Germany)
12:28 Leben mit ITP: Patienten im Fokus R. S. Alesci (Bad Homburg, Germany)
12:51 Klinische Erfahrungen mit dem SYK-Inhibitor Fostamatinib O. Meyer (Berlin, Germany)
12:14 Diskussion A. Matzdorff (Berlin, Germany)
SCIENTIFIC PROGRAM | THURSDAY, 25.02.2021 SCIENTIFIC PROGRAM | THURSDAY, 25.02.2021
4342
13:45 – 15:00Rome
Oral CommunicationsMechanisms of Disease IChairs: D. A. Tsakiris (Basel, Switzerland), D. Bertaggia Calderara (Lausanne, Switzerland)
13:45 Factor Xa and factor IIa inhibitors differentially regulate inflammation in myocardial ischemia reperfusion injury I. Gadi, S. Fatima, S. Kohli, A. Elwakiel, B. Isermann, K. Shahzad (Leipzig)
13:55 Von Willebrand factor (vWF) significantly modifies the sedimentation profile of FVIII-containing immune complexes (FVIII-IC) based on the type of an-ti-FVIII antibodies O. Oleshko, U. Curth, A. Tiede, S. Werwitzke (Hannover)
14:05 Characterization of activity and cleavage of von Willebrand disease type 2B variants M. A. Brehm, Y. Yildiz, K. Lehmann, T. Obser, A. Mojzisch, S. Peine, S. Schneppenheim, U. Budde, R. Schneppenheim (Hamburg)
14:15 Impact of osteopontin on platelet adhesion and activation in intraluminal thrombus formation and abdominal aortic aneurysm progression C. Böddeker, M. Wagenhäuser, W. Ibing, A. Ehrenberg, H. Schelzig, M. Elvers (Düsseldorf)
14:25 Impact of platelets and red blood cells in abdominal aortic aneurysm K. J. Krott, M. Wagenhäuser, A. Ehrenberg, T. Feige, A. Beele, E. Schickentanz-Dey, H. Schelzig, M. Elvers (Düsseldorf)
14:35 Q&A
13:45 – 15:15Barcelona
Oral CommunicationsPediatrics & Gynecology-ObstetricsChairs: M. Rizzi (Lausanne, Switzerland), D. Surbek (Bern, Switzerland)
13:45 State of the Art: Child with Haemophilia; from pregnancy to birth S. Halimeh (Duisburg, Germany)
14:10 Differences in the coagulation profile in women with mild and severe eclampsia E. Lefkou1, 2, A. Rousseau3, P. Vandreden3, 2, L. Papageorgiou2, G. Gerotziafas2 (1Thessaloniki, 2Paris, 3Gennevilliers)
14:20 Acquired von Willebrand Syndrom (avWS) Typ 2 in children with severe pulmonary arterial hypertension (PAH) I. Wieland, K.-A. Lambeck, G. Hansmann (Hannover)
14:30 Human Fibrinogen Concentrate for Bleeding Prophylaxis During Surgery in Paediatric Patients with Congenital Fibrinogen Deficiency C. Djambas Khayat1, S. D. Lohade2, F. D‘Souza3, L. S. Gowda4, O. Zekavat5, I. Kruzhkova6, B. Schwartz7, C. Solomon6, F. Peyvandi8 (1Beirut, 2Pune, 3Bangalore, 4Devangere, 5Shiraz, 6Lachen, 7New Jersey, 8Milan)
14:40 The Bacteria-Associated Thrombosis, Thrombophlebitis and LEmierre syndrome (BATTLE) registry: background and rationale. L. Valerio1, G. Corsi2, T. Sebastian3, S. Barco1, 3 (1Mainz, 2Bologna, 3Zurich)
14:50 Q&A
13:45 – 15:15Sydney
Oral CommunicationsMegakaryocytes, Platelets & VWF Chairs: P. Fontana (Geneva, Switzerland), C. James (Bordeaux, France)
13:45 Light-induced ion influx triggers megakaryocyte polarization Y. Zhang, S. Gao, J. Yu-Strzelczyk, H. Kurz, G. Nagel, M. Bender (Würzburg)
13:55 Antibodies protect platelet damage by pneumolysin S. Handtke, K. Jahn, R. Palankar, T. P. Kohler, J. Wesche, S. Hammerschmidt, A. Greinacher (Greifswald)
14:05 Low adhesion and interaction forces of Myh9 mutant platelets lead to impaired clot retraction and unstable thrombus formation J. Baumann1, L. Sachs2, Z. Nagy1, I. Schön3, A. Greinacher2, O. Otto2, R. Palankar2, M. Bender1 (1Würzburg, 2Greifswald, 3Dublin)
14:15 Platelets from patients with MYH9 related disorders are mechanically stiffer L. Sachs1, J. Baumann2, J. Wesche1, P. Nestler1, C. Zaninetti1, L. Lenkeit1, A. Greinacher1, M. Bender2, O. Otto1, R. Palankar1 (1Greifswald, 2Würzburg)
14:25 Epinephrine enhances platelet aggregation at the expense of procoagulant activity A. Aliotta, D. Bertaggia Calderara, M. G. Zermatten, L. Alberio (Lausanne)
14:35 Phosphorylation and activation of Pannexin-1 upon platelet activation and thrombus formation L. M. Metz (Duesseldorf)
14:45 Q&A
14:15 – 15:30Lausanne
BDDH-Sitzung
15:30 – 16:30Rome
PlenaryPhysicians Across BordersChair: L. Alberio (Lausanne, Switzerland)
15:30 Homo cogitansA-M. Jerumanis (Lugano, Switzerland)
16:00 Homo digitalis T. Gantner (Köln, Germany)
SCIENTIFIC PROGRAM | THURSDAY, 25.02.2021 SCIENTIFIC PROGRAM | THURSDAY, 25.02.2021
4544
SCIENTIFIC PROGRAM | THURSDAY, 25.02.2021
16:45 – 18:15Rome
State of the ArtPediatrics Chairs: M. Albisetti (Zurich, Switzerland), F. Achini (Zurich, Switzerland)
16:45 Current state of antithrombotic treatment in children M. Rizzi (Lausanne, Switzerland)
17:05 Acute recanalization therapies in pediatric ischemic stroke: PRO S. Bigi (Bern, Switzerland)
17:25 Acute recanalization therapies in pediatric ischemic stroke: CONTRA Ch. Male (Vienna, Austria)
17:45 Q&A
16:45 – 18:15Barcelona
State of the ArtCardiologyChairs: M. Valgimigli (Lugano, Switzerland), R. Al-Lamee (London, United King-dom)
16:45 Current concepts on the pathophysiology of coronary artery disease St. Fournier (Lausanne, Switzerland)
17:05 Aspirin-free treatment strategies in patients with acute coronary syndromes R. Mehran (New York, United States)
17:25 Combining antiplatelets and anticoagulants in patients with chronic c oronary syndrome M. Roffi (Geneva, Switzerland)
17:45 Q&A
16:45 – 18:15Sydney
State of the ArtProcoagulant PlateletsChairs: K. Jurk (Mainz, Germany), A. Alliotta (Lausanne, Switzerland)
16:45 Mechanisms of procoagulant COATed platelet generation M. Panteleev (Moscow, Russia)
17:05 How to study platelet procoagulant function S. Ramström (Örebro, Sweden)
17:25 The role of cyclophilin D in platelet function M. Rondina (Salt Lake City, United States)
17:45 Q&A
16:45 – 18:15Lausanne
State of the ArtHemato-oncology BChairs: W. Wuillemin (Lucerne, Switzerland), J. Riedl (Vienna, Austria)
16:45 Currents concepts on pathophysiology and treatment of BCR-ABL-negative myeloproliferative neoplasms S. Meyer (Basel, Switzerland)
17:05 Prevention and management of thrombosis in BCR-ABL-negative myelopro-liferative neoplasms A. Falanga (Bergamo, Italy)
17:25 Management of pregnancy in BCR-ABL-negative myeloproliferative neoplasms M. Griesshammer (Minden, Germany)
17:45 Q&A
16:45 – 18:15Seoul
State of the ArtNew treatmentsChairs: TBD, TBD
16:45 Emerging new treatments in immune thrombocytopenia N. Cooper (London, United Kingdom)
17:05 Novel platelet targets for anti-thrombotic treatment M. Jandrot-Perrus (Paris, France)
17:25 Emerging anticoagulant strategies J. I. Weitz (Hamilton, Canada)
17:45 Q&A
18:30 – 20:30Rome
GTH Mitgliederversammlung
SCIENTIFIC PROGRAM | THURSDAY, 25.02.2021
47
SCIENTIFIC PROGRAM | FRIDAY, 26.02.2021
10:00 – 11:00Rome
Ausstellerbeiratssitzung
10:00 – 11:00 Master ClassHow to choose the correct anticoagulation for the general cardiologypatient?Tutor: C. Herrera Siklódy (Lausanne, Switzerland)
11:00 – 12:00 Master ClassViscoelastic methodsTutor: C. Marcucci (Lausanne, Switzerland), E. Scala (Lausanne, Switzerland)
11:00 – 12:00 Master ClassUse of mouse models of platelet depletion and transfusion for in vivo as-sessment of platelet functionTutor: B. Hechler (Strasbourg, France)
12:00 – 13:30Rome
Satellite Symposium Biotest AGDas Bewährte trifft auf das UnbekannteChair: J. Schüttrumpf (Dreieich, Germany)
12:00 Einführung J. Schüttrumpf (Dreieich, Germany)
12:10 Die Behandlung von PUPs R. Knöfler (Dresden, Germany)
12:30 Die Behandlung der Erworbenen HämophilieJ. Oldenburg (Bonn, Germany)
12:50 Revolutioniert CRISPR-Cas die Gentherapie? T. Cathomen (Freiburg, Germany)
13:20 Diskussion
12:00 – 13:30Barcelona
Satellite Symposium Sanofi GenzymeNot the usual suspects – thrombocytopenias in clinical practiceChair: J. A. Kremer Hovinga (Bern, Switzerland)
12:00 Introduction J. A. Kremer Hovinga (Bern, Switzerland)
12:05 Seemingly perfect crimes - when TTP comes in disguise Ch. von Auer (Mainz, Germany)
12:35 Wrongly accused suspects in Morbus Gaucher patientsM. Bommer (Göppingen, Germany)
13:05 Q&A
Platzhalter Inserat
4948
SCIENTIFIC PROGRAM | FRIDAY, 26.02.2021 SCIENTIFIC PROGRAM | FRIDAY, 26.02.2021
12:00 – 13:30Sydney
Satellite Symposium Siemens Healthcare GmbHAutomatisierte Thrombozytenfunktionstestung – ein UpdateChair: U. Scholz (Leipzig, Germany)
12:00 Einführung in die Thrombozytenaggregation nach Born - Möglichkeiten und Grenzen I. Birschmann (Bad Oeynhausen, Germany)
12:15 Guidelines als Herausforderung eines zertifizierten Labors M. Krause (Leipzig, Germany)
12:35 Integrierte Thrombozytenaggregation - Anwendung in der Routine K. Kirchmayr (Amberg, Germany)
12:50 Automatisierte Thrombozytenaggregation - Klinische Evaluierung und ent-sprechende Beispiele F. Prüller (Graz, Austria)
13:10 Q&A
13:45 – 15:00Rome
Oral CommunicationsCOVID-19Chairs: Th. Lecompte (Geneva, Switzerland), J. Helms (Strasbourg, France)
13:45 State of the Art: ? TBD
14:10 Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19 G. Gerotziafas1, T. Sergentanis2, G. Voiriot1, L. Lassel1, C. Papageorgiou1, A. Elabbadi1, M. Turpin1, P. Vandreden3, 1, L. Papageorgiou1, T. Psaltopoulou2, E. Terpos2, M. A. Dimopoulos2, A. Parrot1, J. Cadranel1, G. Pialloux1, I. Elalamy1, M. Fartoukh1 (1Paris, 2Athens, 3Gennevilliers)
14:20 Prothrombotic alterations of von Willebrand factor level and ADAMTS13 activity in hospitalized COVID-19 patients G. Sinkovits, B. Mezó, M. Réti, V. Müller, Z. Iványi, J. Gál, L. Gopcsa, P. Reményi, B. Szathmáry, B. Lakatos, J. Szlávik, I. Bobek, Z. Z. Prohászka, Z. Förhécz, D. Csuka, L. Hurler, E. Kajdácsi, L. Cervenak, P. Kiszel, T. Masszi, I. Vályi-Nagy, Z. Prohászka (Budapest)
14:30 Platelet activation and apoptosis in COVID-19 infection: data from an observational study K. Althaus, I. Marini, J. Zlamal, L. Pelzl, H. Häberle, M. Mehrländer, S. Hammer, M. Bitzer, N. Malek, D. Rath, H. Bösmüller, M. Gawaz, P. Rosenberger, T. Bakchoul (Tübingen)
14:40 Incidence of Thrombosis and Associated Risk Factors in Hospitalized CO-VID-19 Patients in a New York City Hospital System P. Theprungsirikul, S. E. Saith (New York)
14:50 Q&A
13:45 – 15:00Barcelona
Oral CommunicationsCrosstalks between Hemostasis and other SystemsChairs: V. Schröder (Bern, Switzerland), TBD
13:45 State of the Art: ? TBD
14:10 LMWH prevents platelet and extracellular vesicle mediated thrombo- inflammation S. Kohli, K. Singh, A. Gupta, M. Lia, H. Stepan, B. Isermann (Leipzig)
14:20 Platelet-derived chemokines regulating neutrophil activation stages in arterial thrombus formation C. Schoenichen1, 2, M. Nagy1, S. Brouns1, S. Montague3, 4, F. Ní Áinle5, K. Knoops1, R. Koenen1, O. Soehnlein6, S. Watson4, J. Heemskerk1 (1Maastricht, 2Mainz, 3Canberra, 4Birmingham, 5Dublin, 6Munich)
14:30 Severity of Transfusion-Related Acute Lung Injury in mice expressing human FcgRIIA is determined by platelet-released serotonin M.-B. El Mdawar1, B. Maître1, S. Magnenat1, F. Tupin1, F. Jönsson2, C. Gachet1, H. de la Salle1, B. Hechler1 (1Strasbourg, 2Paris)
14:40 The contribution of bile acid transport and endoplasmatic reticulum stress to tissue factor activation in hepatocytes A. Schlagenhauf, S. Pohl, T. Greimel, K. Meinel, V. Aguiriano-Moser, S. Gallistl, J. Jahnel, H. Haidl (Graz)
14:50 Q&A
13:45 – 15:00Sydney
Oral CommunicationsDiagnostic laboratory: Today & tomorrow Chairs: M. Nagler (Bern, Switzerland), Y. Henskens (Maastricht, Netherlands)
13:45 A Comparison of Functional Methods with Absolute Quantification of Heparin Levels in Clinical Samples by Heparin Red Assay E. Bontekoe1, F. Siddiqui1, D. Hoppensteadt1, A. Kouta1, J. Fareed1, R. Kraemer2 (1Maywood, IL, 2Heidelberg)
13:55 Heparinase treatment to remove the inhibitory heparin effect on the thrombin generation assay A. Weber, M. LLusa, N. B. Binder, H. Gritsch (Vienna)
14:05 Use of a Universal Calibrator for Direct FXa inhibitor DOACs S. Geiter, M. Unterberger, N. B. Binder (Vienna)
14:15 A universal anti-Xa assay for the determination of rivaroxaban, apixaban, and edoxaban drug levels: development, diagnostic accuracy, and external validation G. Willekens1, 2, J. D. Studt3, A. Mendez4, L. Alberio5, P. Fontana6, W. A. Wuille-min7, A. Schmidt8, L. Graf9, B. Gerber10, C. Bovet2, M. Nagler2 (1Maastricht, 2Bern, 3Zürich, 4Aarau, 5Lausanne, 6Geneva, 7Lucerne, 8Zurich, 9St. Gallen, 10Bellinzona)
5150
14:25 Robust and selective chromogenic measurement of factor VIII activity with an antibody-based factor VIII chromogenic assay A. Weber, A. Engelmaier, S. Haindl, M. Zivsa, G. Mohr, K. Großschopf-Abele, C. Zlabinger (Vienna)
14:35 Application of the STG-Bleedscreen assay in clinical routine T. Siegemund, A. Siegemund, H. Bönigk (Magdeburg)
14:45 Q&A
13:45 – 15:00Lausanne
Oral CommunicationsMechanisms of Disease II Chairs: L. M. Asmis (Zurich, Switzerland), M. Bachler (Innsbruck, Austria)
13:45 Upregulated autophagy in antigen-presenting splenic cells hints at promotion of immune-mediated thrombotic thrombocytopenic purpura (iTTP) M. Schaller, M.-P. Tschan, J.-A. Kremer Hovinga (Bern)
13:55 Microvascular immune cell recruitment regulating development of immunothrombosis in systemic bacterial infection T. Mueller, S. Meister, M. Thakur, M. Wohlrab, S. Bortoluzzi, N. Jensen, M. Rossner, M. Schmidt-Supprian, S. Massberg, B. Engelmann (Munich)
14:05 Dietary omega-3 fatty acid reverses age-associated platelet hyperreactivity through modulation of gut microbiota S. S. Saeedi Saravi1, 2, N. R. Bonetti1, 2, B. Pugin1, F. Constancias1, L. Pasterk1, S. Gobbato2, A. Akhmedov1, L. Liberale1, T. F. Lüscher1, G. G. Camici1, J. H. Beer2, 1 (1Zurich, 2Baden)
14:15 The Glycosylation Nexus Enigma: new clues to the role of the GNE gene in the pathogenesis of inherited thrombocytopenia in both isolated and myopathy-associated forms I. Persico1, R. Bottega1, F. Faletra1, D. Simoncini2, G. Robustelli2, A. M. Bianco1, A. Pastore3, M. Agosti2, P. Grotto4, M. Gabelli5, A. Biffi5, A. Burlina5, M. Marinoni2, A. Marzollo5, P. Noris6, A. Savoia1 (1Trieste, 2Varese, 3London, 4Treviso, 5Padua, 6Pavia)
14:25 Platelet Distribution Width as a marker of platelet reactivity and platelet activation status in men and women of the Moli-family cohort B. Izzi1, A. Gialluisi1, F. Gianfagna2, 3, S. Orlandi1, A. De Curtis1, S. Magnacca2, M. B. Donati1, G. de Gaetano1, M. F. Hoylaerts4, C. Cerletti1, L. Iacoviello1, 3 (1Pozzilli (IS), 2Napoli, 3Varese, 4Leuven)
14:35 Q&A
15:30 – 16:30Rome
PlenaryThink Across Borders Chairs: I. Pabinger-Fasching (Vienna, Austria)
15:30 Fibrinolysis and PsycheR. Medcalf (Melbourne, Australia)
16:00 Ants and Medicine L. Keller (Lausanne, Switzerland)
16:45 – 18:15Rome
State of the ArtTransfusion medicine Chairs: M. Daskalakis (Bern, Switzerland), N. Worel (Vienna, Austria)
16:45 Metabolism of stored platelet concentrates H. Feys (Gent, Belgium)
17:05 Effects and side-effects of platelet transfusion F. Cognasse (Saint-Etienne, France)
17:25 New trends in transfusion medicine: cold platelets A. Cap (Houston, United States)
17:45 Q&A
16:45 – 18:15Barcelona
State of the ArtVenous Thromboembolism Chairs: H. Robert-Ebadi (Geneva, Switzerland) M. Rizzi (Lausanne, Switzerland)
16:45 Variables affecting catheter related thrombosis in children: interventional radiology point of view R. Gnannt (Zurich, Switzerland)
17:05 Screening for cancer in patients with acute venous thromboembolic disease M. Blondon (Geneva, Switzerland)
17:25 Duration of anticoagulant treatment C. Becattini (Perugia, Italy)
17:45 Q&A
16:45 – 18:15Sydney
State of the ArtTreatment challengesChairs: P. Fontana (Geneva, Switzerland), S. Susen (Lille, France)
16:45 Management of cardiovascular disease in hemophilia J. Oldenburg (Bonn, Germany)
17:05 Anticoagulation in patients with platelet disorders Th. Thiele (Greifswald, Germany)
17:25 Interactive clinical cases B. Lämmle (Bern, Switzerland)
17:45 Q&A
SCIENTIFIC PROGRAM | FRIDAY, 26.02.2021 SCIENTIFIC PROGRAM | FRIDAY, 26.02.2021
52
16:45 – 18:15Lausanne
State of the ArtLaboratory methodsChairs: J-D. Studt (Zurich, Switzerland), TBD
16:45 Diagnosing hereditary platelet disorders: Modalities and consequences A. Greinacher (Greifswald, Germany)
17:05 Thrombin generation and fibrin clot formation assays: Ready for prime time? A. Tripodi (Milano, Italy)
17:25 Measuring fibrinolysis C. Longstaff (South Mimms, United Kingdom)
17:45 Q&A
18:30 – 19:00 Closing Ceremony
SCIENTIFIC PROGRAM | FRIDAY, 26.02.2021
Platzhalter Inserat
5554
POSTER LIST POSTER LIST
P 1 Beispiel Titel Hans Muster
5756
POSTER LIST POSTER LIST
5958
LIST OF CHAIRS, SPEAKERS AND AUTHORS LIST OF CHAIRS, SPEAKERS AND AUTHORS
Lorenzo Alberio, Lausanne (CH)
4, 7, 8, 9, 24, 43, 49
Lorenzo Alberio, Lausanne (CH)
4, 7, 8, 9, 24, 43, 49
Chairs / Speakers / Authors Page Chairs / Speakers / Authors Page Chairs / Speakers / Authors Page Chairs / Speakers / Authors Page
6160
INDUSTRIAL EXHIBITION
Platzhalter Standplan
Ausstellerliste
No.
Beispiel Aussteller 25
62
LIST OF SPONSORS
Platzhalter Inserat "Bristol"
Company City Country
Alexion Pharma Germany GmbH Munich Germany
Bayer Vital GmbH Leverkusen Germany
BioMarin Deutschland GmbH Kronberg Germany
Biotest AG Dreieich Germany
Bristol-Myers Squibb GmbH & Co. KGaA und Pfizer Pharma GmbH
Berlin Germany
CSL Behring GmbH Hattersheim Germany
Grifols Deutschland GmbH Frankfurt am Main Germany
LEO Pharma Neu-Isenburg Germany
LFG GmbH Münster Germany
Mitsubishi Tanabe Pharma GmbH Düsseldorf Germany
Novo Nordisk Pharma GmbH Mainz Germany
Octapharma GmbH Langenfeld Germany
Pfizer Pharma GmbH Berlin Germany
Roche Pharma AG / Chugai Pharma Germany GmbH und Roche Diagnostics Deutschland GmbH
Grenzach-Wyhlen Germany
Sanofi-aventis (schweiz) ag Vernier Switzerland
Siemens Healthcare GmbH Erlangen Germany
Swedish Orphan Biovitrum GmbH Martinsried Germany
Swedish Orphan Biovitrum GmbH Basel Switzerland
Takeda Pharma Vertrieb GmbH & Co. KG Berlin Germany
Platzhalter Inserat "LFB"
